1. Home
  2. ARDX vs NMFC Comparison

ARDX vs NMFC Comparison

Compare ARDX & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • NMFC
  • Stock Information
  • Founded
  • ARDX 2007
  • NMFC 2010
  • Country
  • ARDX United States
  • NMFC United States
  • Employees
  • ARDX N/A
  • NMFC N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • ARDX Health Care
  • NMFC Finance
  • Exchange
  • ARDX Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • ARDX 882.9M
  • NMFC 983.8M
  • IPO Year
  • ARDX 2014
  • NMFC 2011
  • Fundamental
  • Price
  • ARDX $5.57
  • NMFC $9.60
  • Analyst Decision
  • ARDX Strong Buy
  • NMFC Hold
  • Analyst Count
  • ARDX 10
  • NMFC 4
  • Target Price
  • ARDX $10.65
  • NMFC $10.00
  • AVG Volume (30 Days)
  • ARDX 4.4M
  • NMFC 654.5K
  • Earning Date
  • ARDX 10-30-2025
  • NMFC 11-03-2025
  • Dividend Yield
  • ARDX N/A
  • NMFC 13.31%
  • EPS Growth
  • ARDX N/A
  • NMFC N/A
  • EPS
  • ARDX N/A
  • NMFC 0.65
  • Revenue
  • ARDX $398,234,000.00
  • NMFC $340,877,000.00
  • Revenue This Year
  • ARDX $18.90
  • NMFC N/A
  • Revenue Next Year
  • ARDX $31.52
  • NMFC N/A
  • P/E Ratio
  • ARDX N/A
  • NMFC $14.82
  • Revenue Growth
  • ARDX 58.12
  • NMFC N/A
  • 52 Week Low
  • ARDX $3.21
  • NMFC $8.84
  • 52 Week High
  • ARDX $6.78
  • NMFC $12.05
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 52.45
  • NMFC 49.68
  • Support Level
  • ARDX $5.59
  • NMFC $9.50
  • Resistance Level
  • ARDX $6.73
  • NMFC $9.80
  • Average True Range (ATR)
  • ARDX 0.30
  • NMFC 0.16
  • MACD
  • ARDX 0.09
  • NMFC 0.03
  • Stochastic Oscillator
  • ARDX 35.44
  • NMFC 53.78

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

Share on Social Networks: